Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor ConferencesGlobeNewsWire • 11/09/22
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of HematologyGlobeNewsWire • 11/03/22
Allogene Therapeutics (ALLO) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/02/22
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D ShowcaseGlobeNewsWire • 11/02/22
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in AsiaGlobeNewsWire • 10/31/22
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022GlobeNewsWire • 10/26/22
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational ProductsGlobeNewsWire • 10/11/22
Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T TherapyZacks Investment Research • 10/07/22
Allogene Therapeutics Initiates Industry's First Allogeneic CAR T Phase 2 TrialGlobeNewsWire • 10/06/22
Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine SummitGlobeNewsWire • 09/23/22
Allogene Therapeutics (ALLO) Down 10.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/08/22
Allogene Therapeutics, Inc.'s (ALLO) CEO David Chang on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/10/22
Allogene Therapeutics (ALLO) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/09/22
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022GlobeNewsWire • 07/27/22
Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of DirectorsGlobeNewsWire • 07/12/22
Allogene Therapeutics (ALLO) Moves 16.4% Higher: Will This Strength Last?Zacks Investment Research • 06/20/22
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell LymphomaGlobeNewsWire • 06/08/22
Why Is Allogene Therapeutics (ALLO) Down 14.9% Since Last Earnings Report?Zacks Investment Research • 06/03/22
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual MeetingGlobeNewsWire • 05/19/22